Treace Medical Concepts, Inc. (TMCI) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
30/53
2.8 / 5 stars
All 53 Win/Lose results and 67 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinTMCI / S&P 197.01% / 15.20% |
LoseTMCI / S&P -3.95% / 15.00% |
LoseTMCI / S&P 16.46% / 50.40% |
| 2026-Q10/3 |
LoseTMCI / S&P -45.31% / -4.33% |
LoseTMCI / S&P -1.66% / 11.30% |
LoseTMCI / S&P 12.94% / 27.70% |
| 2025-Q40/3 |
LoseTMCI / S&P -63.49% / 2.65% |
LoseTMCI / S&P 1.59% / 9.00% |
LoseTMCI / S&P 3.33% / 13.40% |
| 2025-Q32/3 |
WinTMCI / S&P 14.12% / 8.12% |
WinTMCI / S&P 7.90% / 4.61% |
LoseTMCI / S&P -19.19% / 13.45% |
| 2025-Q21/3 |
LoseTMCI / S&P -29.92% / 10.94% |
WinTMCI / S&P 7.67% / 4.83% |
LoseTMCI / S&P -22.55% / 10.63% |
| 2025-Q12/3 |
WinTMCI / S&P 12.77% / -4.27% |
WinTMCI / S&P 7.54% / 4.98% |
LoseTMCI / S&P -3.41% / 10.57% |
| 2024-Q43/3 |
WinTMCI / S&P 28.28% / 2.41% |
WinTMCI / S&P 11.89% / 5.25% |
WinTMCI / S&P 11.11% / 6.15% |
| 2024-Q32/3 |
LoseTMCI / S&P -12.78% / 5.89% |
WinTMCI / S&P 16.14% / 5.89% |
WinTMCI / S&P 26.92% / 6.11% |
| 2024-Q22/3 |
LoseTMCI / S&P -49.04% / 4.28% |
WinTMCI / S&P 18.90% / 5.38% |
WinTMCI / S&P 41.67% / 5.12% |
| 2024-Q12/3 |
LoseTMCI / S&P 2.35% / 10.56% |
WinTMCI / S&P 26.48% / 5.71% |
WinTMCI / S&P 6.02% / 5.59% |
| 2023-Q41/3 |
LoseTMCI / S&P -2.75% / 11.69% |
WinTMCI / S&P 31.92% / 6.81% |
LoseTMCI / S&P 6.58% / 7.78% |
| 2023-Q32/3 |
LoseTMCI / S&P -48.75% / -3.27% |
WinTMCI / S&P 39.17% / 7.52% |
WinTMCI / S&P -4.88% / -5.03% |
| 2023-Q22/3 |
LoseTMCI / S&P 1.55% / 8.74% |
WinTMCI / S&P 46.37% / 9.50% |
WinTMCI / S&P 0.00% / -8.57% |
| 2023-Q13/3 |
WinTMCI / S&P 9.57% / 7.50% |
WinTMCI / S&P 47.95% / 10.77% |
WinTMCI / S&P 62.75% / -15.69% |
| 2022-Q41/2 |
LoseTMCI / S&P 4.17% / 7.56% |
WinTMCI / S&P 50.22% / 11.88% |
No dataTMCI / S&P / -17.99% |
| 2022-Q32/2 |
WinTMCI / S&P 53.91% / -4.88% |
WinTMCI / S&P 47.51% / 13.47% |
No dataTMCI / S&P / -1.41% |
| 2022-Q21/2 |
LoseTMCI / S&P -24.17% / -16.10% |
WinTMCI / S&P 46.75% / 13.71% |
No dataTMCI / S&P / 11.04% |
| 2022-Q12/2 |
WinTMCI / S&P 1.45% / -4.60% |
WinTMCI / S&P 61.62% / 15.97% |
No dataTMCI / S&P / 42.23% |
| 2021-Q41/2 |
LoseTMCI / S&P -30.71% / 11.03% |
WinTMCI / S&P 64.59% / 15.00% |
No dataTMCI / S&P / 96.40% |
| 2021-Q30/1 |
LoseTMCI / S&P -13.95% / 0.58% |
No dataTMCI / S&P / 10.77% |
No dataTMCI / S&P / 69.42% |
| 2021-Q20/0 |
No dataTMCI / S&P / 8.55% |
No dataTMCI / S&P / 6.58% |
No dataTMCI / S&P / 51.81% |
| 2021-Q10/0 |
No dataTMCI / S&P / 6.17% |
No dataTMCI / S&P / -1.06% |
No dataTMCI / S&P / 7.39% |
| 2020-Q40/0 |
No dataTMCI / S&P / 12.15% |
No dataTMCI / S&P / -3.72% |
No dataTMCI / S&P / -33.42% |
| 2020-Q30/0 |
No dataTMCI / S&P / 8.93% |
No dataTMCI / S&P / -2.04% |
No dataTMCI / S&P / -27.10% |
| 2020-Q20/0 |
No dataTMCI / S&P / 20.54% |
No dataTMCI / S&P / -0.46% |
No dataTMCI / S&P / -27.11% |
| 2020-Q10/0 |
No dataTMCI / S&P / -19.60% |
No dataTMCI / S&P / 3.47% |
No dataTMCI / S&P / -14.75% |
| 2019-Q40/0 |
No dataTMCI / S&P / 9.07% |
No dataTMCI / S&P / 5.36% |
No dataTMCI / S&P / 2.99% |
| 2019-Q30/0 |
No dataTMCI / S&P / 1.70% |
No dataTMCI / S&P / 5.02% |
No dataTMCI / S&P / 0.21% |
| 2019-Q20/0 |
No dataTMCI / S&P / 4.30% |
No dataTMCI / S&P / 6.64% |
No dataTMCI / S&P / 8.65% |
| 2019-Q10/0 |
No dataTMCI / S&P / 13.65% |
No dataTMCI / S&P / 8.12% |
No dataTMCI / S&P / 14.29% |
| 2018-Q40/0 |
No dataTMCI / S&P / -13.52% |
No dataTMCI / S&P / 9.05% |
No dataTMCI / S&P / 18.23% |
| 2018-Q30/0 |
No dataTMCI / S&P / 7.71% |
No dataTMCI / S&P / 10.21% |
No dataTMCI / S&P / 19.06% |
| 2018-Q20/0 |
No dataTMCI / S&P / 3.43% |
No dataTMCI / S&P / 9.03% |
No dataTMCI / S&P / 14.46% |
| 2018-Q10/0 |
No dataTMCI / S&P / -0.76% |
No dataTMCI / S&P / 7.68% |
No dataTMCI / S&P / 12.46% |
| 2017-Q40/0 |
No dataTMCI / S&P / 6.64% |
No dataTMCI / S&P / 7.03% |
No dataTMCI / S&P / 13.82% |
| 2017-Q30/0 |
No dataTMCI / S&P / 4.48% |
No dataTMCI / S&P / 5.68% |
No dataTMCI / S&P / 17.57% |
| 2017-Q20/0 |
No dataTMCI / S&P / 3.09% |
No dataTMCI / S&P / 4.83% |
No dataTMCI / S&P / 17.74% |
| 2017-Q10/0 |
No dataTMCI / S&P / 6.07% |
No dataTMCI / S&P / 3.67% |
No dataTMCI / S&P / 13.32% |
| 2016-Q40/0 |
No dataTMCI / S&P / 3.82% |
No dataTMCI / S&P / 2.09% |
No dataTMCI / S&P / 7.05% |
| 2016-Q30/0 |
No dataTMCI / S&P / 3.85% |
No dataTMCI / S&P / 0.20% |
No dataTMCI / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TMCI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -37.33% | 20.78% |
| Annualized return | -37.33% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | TMCI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.72% | 83.14% |
| Annualized return | -29.61% | 12.86% |
10Y · 2021-04-23 to 2026-08-27
| Metric | TMCI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -81.98% | 319.30% |
| Annualized return | -15.75% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |